Table 2.
Multivariate analyses of risk factors for different other malignancies after CLL diagnosis.
| Multivariate analyses for different OMs | |||||
|---|---|---|---|---|---|
| Risk factor | Category | ORb (95% CI) | p value | HRc (95% CI) | p value |
| Hematological malignancies (excluding Richter transformation, AML and MDS) | |||||
| del(13q) | Positive | 1.67 (0.98–2.85) | 0.06 | – | – |
| AML or MDS | |||||
| FC ± R at any line (before MDS or AML) | Yes | 3.7 (2.79–4.91) | <0.001 | – | – |
| AML or MDS (including only treated patients) | |||||
| FC ± R at any line (before MDS or AML) | Yes | 4.57 (2.19–9.53) | 0.006 | 1.6 (1.12–2.29) | 0.01 |
| Age at diagnosis | 1.04 (1.01–1.08) | <0.001 | – | – | |
| AML or MDS (including only treated patients with mutated IGHV and excluding those with known TP53 aberrations) | |||||
| FC ± R at any line (before MDS or AML) | Yes | 3.59 (1.09–11.81) | 0.035 | – | – |
| All non-Hematological malignancies (excluding non-melanoma skin cancers) | |||||
| Sex assigned at birth | Male | 1.77 (1.49–2.11) | <0.001 | – | – |
| IGHV gene status | Unmutateda | 1.89 (1.6–2.24) | <0.001 | – | – |
| Treatment status (before malignancy) | Treated | – | – | 0.4 (0.3–0.48) | <0.001 |
| Age at diagnosis | – | – | 1.03 (1.03–1.04) | <0.001 | |
| Bladder cancer | |||||
| Sex assigned at birth | Male | 6.36 (3.33–12.16) | <0.001 | – | – |
| Treatment status (before bladder) | Treated | – | – | 0.37 (0.21–0.67) | <0.001 |
| Age at diagnosis | – | – | 1.03 (1.02–1.05) | <0.001 | |
| Breast cancer | |||||
| Sex assigned at birth | Male | 0.3 (0.22–0.4) | <0.001 | – | – |
| Type of treatment (before breast cancer) | Chemotherapy or CIT | 0.55 (0.34–0.89) | <0.001 | – | – |
| IGHV gene status | Unmutateda | 1.83 (1.02–3.26) | 0.042 | – | – |
| Colon cancer | |||||
| Sex assigned at birth | Male | 1.03 (1.01–1.05) | 0.001 | – | – |
| Bronchus and lung cancer | |||||
| IGHV gene status | Unmutateda | 2.09 (1.07–4.09) | 0.03 | – | – |
| Sex assigned at birth | Male | 2.23 (0.84–5.88) | 0.11 | – | – |
| Melanoma | |||||
| IGHV gene status | Unmutateda | 2.41 (1.16–5.01) | 0.02 | – | – |
| Non-melanoma skin cancers | |||||
| Sex assigned at birth | Male | 2.53 (1.81–3.55) | <0.001 | – | – |
| Age at diagnosis | 1.04 (1.02–1.07) | 0.001 | 1.04 (1.02–1.06) | <0.001 | |
| FC ± R | Yes | 1.8 (1.36–2.41) | <0.001 | – | – |
| Prostate cancer | |||||
| Treatment status (before prostate) | Treated | 2.11 (1.12–3.97) | 0.021 | – | – |
OMs, other malignancies; OR, odds ratio; HR, hazard ratio; CI, confidence interval; FC ± R, fludarabine, cyclophosphamide with or without rituximab; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; IGHV, immunoglobulin heavy variable.
Empty cells denote that the respective risk factor was not included in the cure or survival part of the model.
Unmutated: ≥98% germline identity.
OR was used to examine the risk factors associated with the risk of eventually developing the outcome of interest (independently of the time this happens).
HR was used to examine the risk factors associated with the time of outcome development between susceptible subjects.